GSK plc reported on February 26, 2024, that its EAGLE-1 trial for gepotidacin, a potential treatment for gonorrhoea, successfully met its primary efficacy endpoint, showing non-inferiority to existing therapies. This positive outcome is significant given the rising resistance to traditional treatments of gonorrhoea.